The U.S. Food and Drug Administration approved at-home, unsupervised outpatient use of BioXcel Therapeutics' sublingual film drug Igalmi (dexmedetomidine) on November 16, 2026. Initially approved in April 2022 for supervised settings, Igalmi fills a gap in outpatient treatment for agitation affecting 25% to 40% of schizophrenia and bipolar disorder patients. Teva Pharmaceuticals acquired the drug's assets in October 2026 and plans to announce commercialization strategy at a later date.
FDA approval and asset acquisition
- ▪The FDA approved at-home, unsupervised outpatient use of BioXcel Therapeutics' sublingual film drug Igalmi
- ▪BioXcel Therapeutics completed the sale of nearly all its assets, including Igalmi, to a unit of Israel-based Teva Pharmaceuticals last month
- ▪Igalmi, chemically known as dexmedetomidine, was originally approved by the FDA as an orally dissolving film in April 2022 for medically supervised use in adults
Commercial plans and market need
- ▪Teva Pharmaceuticals stated that it will announce commercialization plans for the at-home outpatient use of Igalmi at a later date
- ▪Teva Pharmaceuticals stated that no prior FDA-approved options were available for treating agitation associated with schizophrenia or bipolar disorder in unsupervised outpatient settings
Drug mechanism and Therapeutic goals
- ▪Pharmacologic treatments for agitation aim to provide rapid symptom control while preserving patient safety without continuous inpatient supervision
- ▪Teva said Igalmi targets brain receptors that help reduce stress-related behaviors such as agitation in patients with neurological disorders
Agitation and underlying mental health disorders
- ▪Agitation affects between 25% and 40% of patients diagnosed with schizophrenia or bipolar disorder, according to statements by Teva Pharmaceuticals
- ▪Schizophrenia causes delusions, hallucinations, and disorganized thinking, while bipolar disorder causes severe mood swings
Story comments
Loading comments…